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Abstract
Background—Prazosin (PRZ, an α1-adrenergic receptor antagonist) and naltrexone (NTX, a 
non-specific opioid receptor antagonist) each decrease alcohol drinking when administered to rats 
selectively-bred for high voluntary alcohol drinking (alcohol-preferring, or “P”), and the 
combination of PRZ+NTX decreases alcohol drinking more effectively than does either drug 
alone. Since drug responsiveness can depend on history of alcohol drinking and dependence, we 
investigated whether various schedules of PRZ and NTX administration, alone or in combination, 
are effective in decreasing alcohol drinking in male P rats with a history of protracted voluntary 
alcohol drinking, dependence and repeated withdrawals closely resembling human alcoholism.
Methods—Male P rats became alcohol-dependent during 1 year of ad libitum 24 h/day access to 
food, water and 20% alcohol with repetitive temporary alcohol withdrawals. Four sequential 
studies then addressed effects of oral PRZ (2 mg/kg) and NTX (10 mg/kg), alone or together, on 
alcohol drinking during: 1) daily alcohol access with daily drug treatment, 2) intermittent alcohol 
access with daily drug treatment, 3) intermittent alcohol access with occasional drug treatment, 
and 4) post-deprivation reinstatement of alcohol access.
Results—The combination of PRZ+NTX consistently suppressed alcohol drinking during daily 
or intermittent alcohol access conditions and when drug treatment was either daily or occasional. 
PRZ+NTX was consistently more effective than either drug alone. The reduction in alcohol 
drinking was not due to sedation, motor effects or malaise.
Conclusions—Both daily and “as-needed” treatment with PRZ+NTX are highly effective in 
suppressing daily, intermittent and post-deprivation alcohol drinking in male P rats with a 
protracted history of alcohol dependence and repeated withdrawals. This drug combination may be 
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especially effective for treating individuals with long histories of heavy alcohol abuse, dependence 
and repeated relapse, as commonly encountered in clinical practice.
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INTRODUCTION
Alcoholism remains the most prevalent addictive disease, and development of effective 
treatments is a high priority. The US Food and Drug Administration (FDA)-approved 
pharmacotherapies for alcoholism – disulfiram, acamprosate and naltrexone (oral and 
injectable extended release) - all have limitations to their use and effectiveness (Garbutt, 
2009), and clinical utilization rates remain low (Del Re et al., 2013). Additional 
pharmacotherapy targets, and additional strategies for utilizing available pharmacotherapies, 
are needed in order to maximize benefits of treatment while minimizing adverse side effects.
Brain opioidergic regulation has been studied extensively as a target for pharmacotherapy of 
alcohol use disorders, with a primary focus on naltrexone (NTX) - a non-subtype specific 
opioid receptor antagonist that reduces the reinforcing or euphoriant effects of alcohol 
(Froehlich et al., 2003; Froehlich and Li, 1993; Froehlich and Wand, 1996; Gianoulakis, 
1989; Gianoulakis et al., 1996; Mitchell et al., 2012; O’Malley and Froehlich, 2003; 
Rasmussen et al., 1998; 2002). However, effectiveness of NTX in decreasing alcohol 
drinking is modest (Froehlich et al., 2003; O’Malley and Froehlich, 2003); it is not effective 
for all alcoholic individuals (Garbutt et al., 2005; Kranzler and Van Kirk, 2001; Krishnan-
Sarin et al., 2007; O’Malley et al., 1992; Oncken et al., 2001) and, when it is effective, a 
significant number of alcoholic individuals fail to maintain treatment gains and subsequently 
relapse to heavy drinking (Anton et al., 2006; Garbutt et al., 2005; Krystal et al., 2001).
Noradrenergic regulation also plays an important role in regulation of alcohol drinking. 
Blocking norepinephrine synthesis by pharmacologic suppression of dopamine β-hydrolyase 
(DBH) activity (Amit et al., 1977; Davis et al., 1978; Colombo et al., 2014) or deleting the 
gene encoding DBH (Weinshenker et al., 2000) decreases alcohol self-administration in 
rodents. Administration of clonidine, an α2-adrenergic agonist that decreases presynaptic 
norepinephrine release, likewise decreases alcohol drinking by alcohol-preferring (P) rats 
(Rasmussen et al., 2014), an animal model of alcoholism (Bell et al., 2006). Compelling 
evidence for α1-adrenergic receptor-mediated regulation of alcohol drinking comes from 
studies with prazosin, an α1-adrenergic receptor antagonist that is non-subtype selective 
(similar affinities for α1A, α1B, α1D) and blocks brain α1-adrenergic signaling when 
administered systemically at clinically-relevant doses (Menkes et al., 1981; Rojawski and 
Aghajanian, 1982). Prazosin decreases alcohol withdrawal-induced operant alcohol intake in 
Wistar rats (Walker et al., 2008); decreases voluntary alcohol drinking by P rats (Rasmussen 
et al., 2009a; 2009b); increases latency to first operant response for alcohol by P rats 
(Verplaetse et al., 2012); reduces alcohol drinking throughout prolonged treatment of P rats 
(Froehlich et al., 2013a) or outbred rats (Skelly and Weiner, 2014); blocks initiation of 
alcohol drinking in P rats (Froehlich et al., 2013a); blocks development of alcohol 
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conditioned place preference in mice when microinjected into the brain ventral tegmental 
area (Raskind et al., 2011); and decreases stress-induced reinstatement of alcohol seeking in 
rats (Lê et al., 2011). Prazosin also facilitates abstinence in treatment-seeking alcoholic 
individuals (Simpson et al., 2009) and decreases stress- and cue-induced alcohol craving in 
alcohol-dependent men and women (Fox et al., 2012). The similar α1-adrenergic receptor 
antagonist, doxazosin, likewise reduces alcohol drinking in P rats (O’Neil et al., 2013) and 
in alcohol-dependent patients with a high family history density of alcoholism (Kenna et al., 
2015). This growing body of literature demonstrates that reducing CNS α1-adrenergic 
receptor-mediated activity reduces alcohol drinking and relapse in rodents and humans, 
providing a promising target for effective pharmacotherapy of alcohol use disorders.
Since either NTX or PRZ can decrease alcohol drinking in rodents and humans and both are 
safe, orally-active, well-characterized, inexpensive, FDA-approved for human use and well-
tolerated in clinically-relevant doses, we hypothesized that combining these drugs may be 
useful for treating patients not responsive to either drug alone. This hypothesis was 
supported by our finding that combining PRZ with NTX in a single oral medication 
decreases alcohol drinking more consistently than does either drug alone when administered 
to P rats (Froehlich et al., 2013b).
PRZ and NTX effects on alcohol intake depend on history of alcohol drinking and 
dependence (Walker et al., 2008; Pettinati et al., 2006), so we now investigate whether PRZ 
and NTX, alone or in combination, decrease alcohol drinking in male P rats with a 1 year 
history of 24 h/day voluntary alcohol drinking that produces dependence and that spans the 
period from late adolescence to middle age. Introduction of imposed abstinences simulates 
the repeated withdrawals, temporary abstinences and relapses that are common to the 
clinical course of alcoholism, allowing assessment of whether combined PRZ+NTX 
treatment is likely to be effective in long-term alcoholic patients.
We were also interested in whether continuous drug treatments are more or less effective 
than treatments on an “as-needed” basis, i.e., only when drinking is likely to occur (Sinclair 
JD, 2001). Hence, effects of PRZ and/or NTX were assessed during either daily or 
intermittent alcohol access, together with either daily or occasional drug treatment. Since 
clinical treatment commonly begins during voluntarily- or externally-imposed abstinence, 
we also evaluated whether initiating PRZ+NTX treatment during imposed abstinence 
decreases alcohol intake during reinstatement of alcohol access.
We hypothesized that both daily and “as-needed” treatment with PRZ+NTX would be 
highly effective in suppressing daily, intermittent and post-deprivation alcohol drinking in 
male P rats with a protracted history of alcohol dependence and repeated withdrawals. If so, 
this drug combination potentially could provide an effective new option for treating heavy 
drinking subjects with long history of alcohol abuse, alcohol dependence and repeated 
episodes of abstinence and relapse consistent with characteristics of individuals commonly 
encountered in clinical practice.
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MATERIALS AND METHODS
Subjects
Alcohol-naïve male rats (n = 64) from generation 71 of selective breeding for alcohol 
preference were provided by the Alcohol Research Resource Center of the Indiana Alcohol 
Research Center. The rats were received at 30 days of age and were group housed (3/cage) 
with controlled temperature (21 ± 1°C) and reversed 12-hour (h) light-dark cycle (lights-off 
at 10:00 h; procedures during dark periods were performed with dim red illumination). 
Chow (Laboratory Rodent Diet 5001; PMI Nutrition International, Brentwood, MO) and 
water were available ad libitum at all times throughout the study. Starting at 70 days of age, 
the rats were individually housed in clear plastic cages. Body weight (BW) was determined 
weekly (340 ± 4 g at start of study). All experiments were approved by the VA Puget Sound 
Health Care System IACUC and conducted in compliance with the NIH Guide for the Care 
and Use of Laboratory Animals.
Alcohol and Water Intake
Alcohol solutions were prepared by diluting 95% alcohol (ethanol) with deionized water. 
During 24-h alcohol vs water access, positions of overhead ball-bearing sipper tube water 
and alcohol bottles were alternated daily. During tests of 2-h alcohol vs water intake, alcohol 
and water were presented in 2 glass drinking tubes (100 ml, BioServ, Frenchtown, NJ) with 
open-well side-arms extending through adjacent holes on the front of the cage, with 
positions alternated daily. Intakes were determined by weighing each tube to the nearest 0.1 
g. Alcohol and water tubes on 2 empty cages provided estimated loss due to spillage and/or 
evaporation which was subtracted from intakes. Net alcohol intake was converted to g 
alcohol/kg BW.
Drugs
PRZ hydrochloride and/or NTX hydrochloride (Sigma-Aldrich, St. Louis, MO) were 
incorporated into pieces of sweetened gelatin as previously described (Froehlich et al., 
2013a). PRZ (2 mg/kg), NTX (10 mg/kg), PRZ+NTX (2 and 10 mg/kg, respectively), or 
vehicle (water) alone in approximately 1.8 g of gelatin (determined by BW of each rat) were 
fed to the rats once/day, 45 minutes prior to onset of the 2-h alcohol access period, and were 
confirmed to be consumed within 15 min. We previously reported that these PRZ and NTX 
dosages in gelatin suppressed 2-h alcohol drinking in male P rats without a history of 
prolonged unlimited alcohol drinking (Froehlich et al., 2013b). The half-life of NTX in rats 
is 4 ± 0.9 h (Hussain et al., 1987); the half-life of prazosin in rats has not been determined, 
but is about 3 h in humans (Westfall and Westfall, 2006).
Prolonged Alcohol Drinking and Dependence
Starting at 70 days of age, 49 rats received 24 h/day, 7 day/week access to alcohol (starting 
at 10% v/v alcohol, increasing to 20% by week 4) for 17 weeks which then was restricted to 
5 days/week for another 33 weeks. During weeks 27-28, alcohol access was restricted to 2 
h/day (as training for limited access conditions to be used in later testing), after which 24-h 
alcohol access was restored. Fifteen rats did not receive alcohol. After 50 weeks of alcohol 
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drinking, withdrawal was evaluated at 1500 h following 9-h alcohol deprivation, using the 
protocol of Macey et al. (1996) as previously described (O’Neil et al., 2013). In short, each 
rat was rated on abnormal body posture [broad-based stance or abnormal gait]; tail stiffness 
[rigid, awkwardly bent tail]; and ventromedial distal limb flexion when grasped by the scruff 
of the neck, using scales of 0 to 2 for each measure. The three scores were summed for a 
withdrawal rating of 0 - 6 (0 = undetectable, 6 = severe).
Experimental Design
Following withdrawal testing, 15 rats that had not received alcohol (withdrawal controls) 
were removed from the study. The 49 middle-aged rats with a history of prolonged alcohol 
access were then given 2-h (11:00 to 13:00 h) free choice between 20% (v/v) alcohol and 
water for 5 days/week, and PRZ, NTX, PRZ+NTX or VEH effects on alcohol intake were 
investigated in 4 consecutive experiments (Fig. 1).
Pre-Treatment (week 0)—Each rat received a piece of sweetened gelatin (3 g/kg BW) at 
45 min before each 2-h access to 20% alcohol vs water. Average 2-h alcohol intake during 
this week was used for counterbalanced assignment of rats to 1 of the 4 treatment groups (n 
= 12-13 rats/group) as previously described (Rasmussen et al., 2009a), assuring that the 
groups did not differ in baseline alcohol intake.
Experiment 1: Daily alcohol access, daily drug treatments (weeks 1-3)—Each 
rat received either PRZ (2mg/kg; n=12), NTX (10 mg/kg; n=12), PRZ+NTX (2 and 10 
mg/kg, respectively; n=13) or vehicle (VEH; n=12) in gelatin 45 min before the daily 2-h 
alcohol access period, 5 days/week for 3 weeks. In week 2, it was observed whether each rat 
drank alcohol throughout the initial 10 seconds after placing alcohol and water tubes on the 
front of the cage.
Experiment 2: Intermittent alcohol access, daily drug treatments (weeks 4-5)—
Each rat received the same daily (5 days/week) treatment that it had received in Experiment 
1 (i.e., treatments were not re-randomized), but alcohol access was available only 
intermittently; i.e., for 2 h on days 1, 5 and 8 and for 1 h on day 11 (Fig. 3). On day 8, it 
again was observed whether each rat drank alcohol throughout the initial 10 sec after placing 
alcohol and water tubes on the cage. On days when alcohol was not provided, effects of 
drugs or VEH on consumption of [3% sucrose + 0.125% saccharin] vs water was determined 
during trials of 1 h (day 3), 5 min (day 6) or 2 min (day 9) (Fig. 3). On day 11, tail blood 
was collected after 1-h alcohol access and blood alcohol concentration (BAC) was 
determined by NAD-ADH enzymatic Ethanol Assay (Genzyme Diagnostics, Charlottetown, 
PE, Canada).
Experiment 3: Intermittent alcohol access, occasional drug treatments (weeks 
6-8)—The rats continued to receive intermittent 2-h alcohol access for 3 additional weeks. 
On days 1, 11 and 16 (Fig. 4), alcohol access was preceded by the same treatment that the 
rat had received in Experiments 1 and 2. Rats that received PRZ, NTX or PRZ+NTX during 
Experiments 1-3 were then removed from further study.
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Experiment 4. Drug treatment during post-deprivation reinstatement of 
alcohol access (weeks 9-15)—The 12 rats that had received VEH treatment in 
Experiments 1-3 then received 24-h/day alcohol access for 4 weeks (weeks 9-12), followed 
by 2-week alcohol deprivation (weeks 13-14). In week 15, the rats received oral PRZ+NTX 
(2 and 10 mg/kg, respectively; n=6) or VEH (n=6) on each of 4 days. On treatment days 1 
and 2, no alcohol was provided; on days 3 and 4, 2-h alcohol access was provided as in 
Experiments 1-3.
Data Analysis
Grubbs’ Test (Extreme Studentized Deviate Method) performed with GraphPad QuickCalcs 
(GraphPad Software, San Diego, CA) was used to eliminate outlying (p<0.05) alcohol or 
water intake values that were likely due to leakage or spillage. No more than 1 intake 
determination forany treatment X day was determined to be an outlier.
Alcohol or water intake was analyzed by 2-way (dose X day or dose X week) analysis of 
variance (ANOVA) with repeated measures on day (or week), followed – when significant 
overall F ratios were obtained – by Student-Newman-Keuls (SNK) pairwise comparisons. 
Main effect statistics are reported when there was not a significant interaction requiring dose 
X day (or week) comparisons. Intakes of [sucrose + saccharin] in 1 h, 5 min or 2 min trials, 
as well as BAC following 1-h alcohol intake, were each analyzed by 1-way ANOVA and 
pairwise SNK comparisons. Associations between BAC and alcohol intake were evaluated 
by Pearson’s product-moment correlation analyses. Analyses were performed with 
Sigmaplot 11 software (Systat Software, Inc., Chicago, IL) with significance at p<0.05. Data 
are presented as mean±SEM.
RESULTS
During the 50th week of initial prolonged alcohol access, 24-h alcohol intake was 6.7 ± 0.2 
g/kg, with alcohol preference (alcohol intake / [alcohol + water intake]) of 0.81 ± 0.03. After 
9 h of imposed abstinence, alcohol withdrawal scores were increased relative to control rats 
without a history of alcohol drinking (3.9 ± 0.2 vs 1.1 ± 0.2, respectively; p<0.001, Student 
t-test). After limiting daily alcohol access to 2 h, alcohol intake during the pre-treatment 
week (week 0) was 2.4 ± 0.1 g/kg/2 h, with alcohol preference of 0.98 ± 0.02.
Experiment 1: Daily Alcohol Access, Daily Drug Treatment
Effects of daily alcohol access (5 days/week) and treatment before each alcohol access with 
PRZ (2 mg/kg), NTX (10 mg/kg), PRZ+NTX (2 and 10 mg/kg, respectively) or VEH are 
presented in Fig. 2.
In week 1, there were significant effects of treatment, F(3, 45) = 7.94, p<0.001, and day, 
F(4, 179), p<0.001, on alcohol intake, but no treatment X day interaction. Only PRZ+NTX 
suppressed alcohol intake (p<0.01, relative to VEH). PRZ+NTX also suppressed alcohol 
intake relative to PRZ (p<0.001) or NTX (p<0.05). NTX suppressed alcohol intake, relative 
to PRZ (p<0.05).
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In week 2, there was a significant effect of treatment, F(3, 45) = 8.71, p<0.001, on alcohol 
intake, but no effect of day and no treatment X day interaction. Only PRZ+NTX suppressed 
alcohol intake (p<0.001, relative to VEH). PRZ+NTX also suppressed alcohol intake 
relative to PRZ (p<0.001) or NTX (p<0.01).
In week 3, there were significant effects of treatment, F(3, 45) = 10.91, p<0.001, and day, 
F(4, 180) = 6.96, p<0.001, on alcohol intake, but no treatment X day interaction. Alcohol 
intake was suppressed by PRZ+NTX (p<0.001), PRZ (p<0.05) or NTX (p<0.05), relative to 
VEH. PRZ+NTX also suppressed alcohol intake relative to PRZ (p<0.05) or NTX (p<0.05).
In the first week of treatment, all rats in all treatment groups drank alcohol throughout the 
first 10 seconds following placement of alcohol and water drinking tubes on the cage. By the 
end of week 3, some rats did not, even though all rats were alert and commonly investigated 
the drinking tubes immediately following placement; the % that did drink alcohol in the first 
10 sec was: VEH = 100; NTX = 83; PRZ = 50; PRZ+NTX = 15. The number of rats in each 
treatment group that did vs did not drink alcohol during the first 10 sec were compared for 
the first vs third week of 2-h alcohol access by 2×4 (week × treatment) Chi-square analysis; 
proportions of rats that decreased immediate alcohol drinking during the interval from week 
1 to week 3 were significantly different among treatments (Chi-square = 22.14, 3 df, 
p<0.001).
Experiment 2: Intermittent Alcohol Access, Daily Drug Treatment
Effects of PRZ, NTX, PRZ+NTX or VEH treatment before each intermittent alcohol access 
are presented in Fig. 3. On 3 alcohol access days (days 1, 5 and 8 in Fig. 3), alcohol was 
available for 2 h, whereas on day 11 alcohol was available only 1 h before tail blood 
collection for determination of BAC. Nonetheless, analysis (1-way ANOVA with repeated 
measures on day) of intake in the VEH group on all 4 access days revealed no difference 
among days, suggesting that alcohol intake occurred primarily within the first h (consistent 
with observed behavior) and justifying inclusion of all 4 days in overall analysis of alcohol 
intake. Accordingly, 2-way repeated measures ANOVA on days 1, 5, 8 and 11 revealed 
significant effects of treatment, F(3, 45) = 13.77, p<0.001, and day, F(3, 135) = 20.287, 
p<0.001, on alcohol intake, but no treatment X day interaction. Alcohol intake was 
suppressed only by PRZ+NTX (p<0.001, relative to VEH); PRZ+NTX also suppressed 
alcohol intake relative to PRZ (p<0.001) or NTX (p<0.001).
On days when alcohol was not provided, treatment effects on 1-h intake of [3% sucrose + 
0.125% saccharin] vs water were determined. There was a significant effect of treatment on 
1-h [sucrose + saccharin] intake, F(3, 45) = 14.0, p<0.001; intake was suppressed by PRZ 
(p<0.01), NTX (p<0.001) or PRZ+NTX (p<0.001), relative to VEH (Fig. 4). Since all rats 
were observed to stop consuming the sweet solution within 45 min on day 3, access to 
[sucrose + saccharin] was limited to 5 min on day 6. During this 5 min access, there was a 
significant treatment effect on [sucrose + saccharin] intake, F(3, 45) = 7.2, p<0.001; PRZ
+NTX suppressed [sucrose + saccharin] intake relative to treatment with VEH (p≤0.001), 
PRZ (p≤0.001) or NTX (p<0.05) (Fig. 4). When access to [sucrose + saccharin] was limited 
further to 2 min on (day 9, all rats were confirmed to drink the sweet solution throughout 2 
min. Nonetheless, there was still a significant treatment effect on [sucrose + saccharin] 
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intake, F(3, 45) = 4.1, p<0.05; PRZ+NTX suppressed intake relative to treatment with VEH 
(p<0.05) or PRZ (p<0.05) (Fig. 4).
BAC after 1-h alcohol access on day 11 was 0.064 ± 0.008, 0.009 ± 0.002, 0.007 ± 0.002 or 
0.002 ± 0.000 % (w/v) in the VEH-, PRZ-, NTX- or PRZ+NTX-treated rats, respectively. 
There was a significant treatment effect on BAC, F(3, 43) = 45.0, p<0.001; PRZ, NTX or 
PRZ+NTX suppressed BAC (p<0.001 for each, relative to VEH). PRZ+NTX also 
suppressed BAC relative to PRZ or NTX (p<0.001 for each). BAC was positively correlated 
with preceding 1-h alcohol intake, r = 0.47, p<0.001.
Experiment 3: Intermittent Alcohol Access, Occasional Drug Treatments
The effects of PRZ, NTX, PRZ+NTX or VEH treatment before only 3 of 8 intermittent 
alcohol access periods are presented in Fig. 5. Analysis of alcohol intake in the 8 alcohol 
access days revealed a treatment X day interaction, F(21, 315) = 3.72, p<0.001. On 
treatment day 1, alcohol intake was suppressed by PRZ, NTX or PRZ+NTX (p<0.001 for 
each, relative to VEH) and PRZ+NTX suppressed intake relative to NTX alone (p<0.05). On 
3 subsequent intermittent alcohol access days with no treatments (days 4, 7, 9 in Fig. 5), 
there were no differences in alcohol intake among treatments. On the second drug treatment 
day (day 11), only PRZ+NTX suppressed alcohol intake (p<0.001, relative to VEH); PRZ
+NTX also suppressed intake relative to PRZ (p<0.01) or NTX (p<0.05). On the next 
alcohol access day (day 14), with no treatment (day 14), alcohol intake nonetheless 
remained suppressed in rats treated with PRZ+NTX on the previous alcohol access day, 3 
days prior (p<0.05). On the third treatment day (day 16), alcohol intake was decreased by 
PRZ (p<0.05), NTX (p<0.01) or PRZ+NTX (p<0.001); PRZ+NTX also suppressed intake 
relative to PRZ (p<0.01) or NTX (p<0.05).
Maintenance of Treatment Effectiveness in 8 Consecutive Weeks
Although different alcohol access and treatment schedules were used, each rat received the 
same drug or VEH treatment throughout Experiments 1–3. Alcohol and water intakes on 
treatment days were further analyzed as weekly averages in all 8 weeks of the 3 experiments 
(Fig. 6),.revealing a treatment X week interaction, F(21, 315) = 2.58, p<0.001. PRZ 
suppressed alcohol intake in weeks 3 and 5 (p<0.05), 6 (p <0.001) and 8 (p<0.01), relative to 
VEH; NTX suppressed intake in weeks 3 (p<0.05), 6 and 8 (p<0.001). PRZ+NTX 
suppressed alcohol intake in all 8 weeks (p<0.001 in each). PRZ+NTX also suppressed 
alcohol intake relative to PRZ in 7 of the 8 weeks (p≤0.001 in weeks 1, 2, 4, 5 and 8; p<0.01 
in 3 and 7); in week 6, suppression of intake by PRZ+NTX, relative to PRZ, was nearly 
significant (p=0.052). PRZ+NTX also suppressed alcohol intake relative to NTX in all 8 
weeks (p≤0.001 in weeks 4-5; ≤0.01 in 2, 3, 6-8; <0.05 in 1). Analysis of average water 
intake on treatment days in all 8 weeks also revealed a treatment X week interaction, F(21, 
315) = 4.04, p<0.001. PRZ increased water intake in weeks 6 and 7 (p<0.001 in each, 
relative to VEH). PRZ+NTX increased water intake in weeks 5, 7 and 8 (p<0.01, 0.001 and 
0.05, respectively). Inspection of the results (Fig. 6) suggests a consistent trend for PRZ and 
PRZ+NTX to increase water intake in all weeks, although differences are not significant 
until week 5; no treatment suppressed water intake.
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BW During 8 Consecutive Weeks of Treatment
Analysis of BW in the pre-treatment week and each of the 8 treatment weeks in Experiments 
1 - 3 (data not shown) revealed no significant differences in BW among treatments or among 
weeks, and no treatment X week interaction. Mean ± SE BW before and after 8 weeks of 
treatment are shown in Table 1.
Experiment 4: Drug Treatment During Post-Deprivation Reinstatement of Alcohol Access
The effect of oral PRZ+NTX (2 and 10 mg/kg, respectively) vs VEH administration on each 
of the final 2 days of 2-week alcohol deprivation and at 45 min before 2-h alcohol access on 
each of 2 subsequent days is shown in Fig. 7. PRZ+NTX suppressed alcohol intake, relative 
to VEH (n=6/treatment), F(1, 11) = 13.89, p<0.01, independent of day (Fig. 7). PRZ+NTX 
increased water intake, F(1, 10) = 7.16, p<0.05, independent of day (average water intake: 
0.21 ± 0.11 or 1.75 ± 0.74 g/kg/2 h for VEH- or PRZ+NTX-treated rats, respectively).
DISCUSSION
Unlimited (24 h/day) voluntary alcohol drinking by male P rats, starting at the transition 
from adolescence and continuing well into middle age, interrupted by repeated imposed 
abstinences, simulated the prolonged alcohol drinking history, repeated episodes of self- or 
externally-imposed alcohol abstinence, and alcohol dependence characteristic of many 
heavy-drinking patients seeking treatment for alcohol use disorders. We previously 
demonstrated that combining PRZ and NTX in a single oral medication decreases alcohol 
drinking more effectively than does either drug alone in male P rats without this prolonged 
history of extensive alcohol drinking and dependence (Froehlich et al., 2013b); here we 
evaluate whether these treatments are likewise effective in this animal model of heavy-
drinking subjects with a prolonged history of alcohol dependence and withdrawals, and - if 
so - under what conditions.
Oral PRZ+NTX (2 and 10 mg/kg, respectively) suppressed 2-h/day alcohol intake on the 
first treatment day and consistently throughout 8 weeks of treatment. Oral PRZ alone or 
NTX alone were not effective until treatment week 3, and suppression of alcohol intake by 
PRZ or NTX was less consistent and smaller than that produced by PRZ+NTX. PRZ+NTX 
consistently decreased alcohol drinking under all conditions investigated (daily alcohol 
access with daily treatments; intermittent alcohol access with daily treatments; and 
intermittent alcohol access with occasional treatments). Under all conditions, PRZ+NTX 
decreased voluntary alcohol drinking more effectively than either drug alone, without loss of 
effectiveness during 8 weeks of treatment. When the subset of rats that had received only 
VEH during the 8 treatment weeks were provided with additional prolonged 24 h/day 
alcohol access followed by 2 weeks of imposed abstinence, PRZ+NTX treatment initiated 2 
days before alcohol reinstatement and continuing during 2 days of 2-h/day alcohol access 
likewise suppressed alcohol intake, comparable to suppression in rats treated with PRZ
+NTX for 8 weeks.
The oral PRZ and NTX doses used in this study (2 and 10 mg/kg, respectively) are the same 
as those previously demonstrated to produce additive suppression of alcohol drinking in 
Rasmussen et al. Page 9
Alcohol Clin Exp Res. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
male P rats without a history of prolonged unlimited alcohol drinking and dependence 
(Froehlich et al., 2013b). As previously discussed (Froehlich et al., 2013b), the oral NTX 
dose is higher than non-oral doses because NTX bioavailability is low when administered 
orally to rats (1% in rats vs 5-40% in humans). In contrast, bioavailability of oral PRZ is 
high, so doses that are effective intraperitoneally (Rasmussen et al., 2009a,b) are similarly 
effective orally (Froehlich et al., 2013a).
The ability to drink alcohol was not compromised by sedation, motor effects or malaise. 
After one week of treatment, all rats - regardless of treatment – drank alcohol throughout the 
first 10 seconds following presentation of alcohol and water tubes through the cage wall, 
confirming that all remained highly motivated, and capable, to drink alcohol. By week 3, all 
VEH-treated rats continued to drink alcohol in the first 10 seconds but many drug-treated 
rats did not, even though they were alert and investigated the tubes immediately. This delay 
in onset of alcohol drinking occurred most frequently in rats receiving daily PRZ+NTX and 
may reflect decreased reinforcing effects of alcohol. Development of aversive post-
ingestional consequences of alcohol is unlikely since water and food intakes were not 
suppressed. Instead, PRZ or PRZ+NTX commonly increased water intake (Fig. 6). 
Stimulation of water drinking by PRZ, alone or combined with NTX, is consistent with 
previous studies (Rasmussen et al., 2009a,b, 2011; Froehlich et al., 2013a,b) and 
demonstrates that inhibition of alcohol drinking is not due to motor impairment. Increased 
water drinking due to blockade of α1-adrenergic neurotransmission may reflect 
hypotension-induced thirst or a centrally-mediated inhibitory effect of norepinephrine on 
water intake, as previously discussed (Froehlich et al., 2013b; O’Neil et al., 2013).
PRZ and/or NTX decreased intake of [sucrose + saccharin] during 1-h access, consistent 
with a report that these drugs can reduce sucrose-reinforced behaviors in P rats (Verplaetse 
and Czachowski, 2015). All treatment groups (including VEH) stopped drinking this sweet 
solution before 1-h access ended, suggesting that PRZ, NTX or PRZ+NTX each decreased 
the amount of sweet solution voluntarily consumed, reflecting decreased thresholds for 
satiety. Only PRZ+NTX decreased intake of the solution when available for 5 or 2 min. 
Since all rats were confirmed to drink the solution throughout the 2 min access, PRZ+NTX 
appears also to have decreased the rate of drinking sweet solution, potentially reflecting 
decreased avidity. Suppression of [sucrose + saccharin] drinking by PRZ and/or NTX 
suggests that effects of these drugs on alcohol drinking may be due in part to generalized 
suppression in intake of highly reinforcing substances, consistent with overlap of neural 
circuits in addiction and obesity (Volkow et al., 2008). However, daily PRZ and/or NTX for 
8 weeks did not alter BW, suggesting that caloric intake and metabolic regulation were 
maintained.
PRZ and/or NTX also decreased BAC after 1-h alcohol access. BAC was positively 
correlated with alcohol intake, suggesting that lower BAC in drug-treated groups was 
secondary to reduction of alcohol intake.
Occasional PRZ+NTX treatment was highly effective in reducing intermittent alcohol 
drinking on the day of treatment, suggesting that this drug combination may be effective 
clinically when administered “as-needed”. This is consistent with evidence that NTX 
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treatment only at times when drinking is anticipated to occur is more effective than chronic 
NTX (Sinclair JD, 2001), as well as with evidence that as-needed treated with the similar 
opioid antagonist, nalmefene, likewise reduced alcohol drinking in alcohol-dependent 
patients (Mann et al., 2013). Evidence that effects of PRZ+NTX treatment prior to one 
intermittent alcohol access can - without further treatment - carry over to a subsequent 
alcohol access 3 days later (Fig. 5) suggests that “as needed” treatment potentially even 
could provide benefit during a subsequent untreated episode of alcohol drinking, which 
requires additional investigation.
PRZ+NTX for treatment of alcohol use disorders offers potential advantages. PRZ may be 
most effective for individuals who drink to avoid aversive effects of excessive noradrenergic 
activation, such as anxiety and hyper-reactivity during abstinence, whereas NTX may be 
most effective for individuals who drink for reinforcing or euphoriant effects of alcohol. 
PRZ+NTX may thus be useful for treating multiple, probably overlapping, subject 
subpopulations as well as for decreasing vulnerability to alcohol drinking at multiple stages 
of alcohol abuse, addiction, withdrawal and abstinence. This and our preceding study 
(Froehlich et al., 2013b) also demonstrate that PRZ+NTX provides greater effectiveness 
than either drug alone. We presented evidence elsewhere that the combined effect in non-
dependent male P rats is due to additivity of responses to the separate drugs (Froehlich et al., 
2013b). However, under some conditions combining PRZ and NTX may also counteract an 
undesirable side effect of one of the drugs. For example, NTX blocks opioid suppression of 
forebrain noradrenergic neurons in the locus coeruleus, blocks opioid suppression of 
corticotropin-releasing factor (CRF) neurons innervating these noradrenergic neurons, and 
blocks opioid suppression of signaling in noradrenergic projection sites, including 
stimulatory noradrenergic innervation of CRF neurons (Koob, 2008; Dunn et al., 1992; 
Strahlendorf et al., 1980; Nakamura et al., 1982; Curtis et al., 1997), thus increasing 
activation of noradrenergic and CRF signaling that is suggested to increase (rather than 
decrease) stress responses and associated alcohol drinking under some conditions (Koob, 
2008). Combining PRZ with the NTX likely decreases the undesired noradrenergic 
activation, potentially allowing full expression of NTX suppression of alcohol drinking - 
perhaps at lower doses - and decreasing potential noradrenergic-mediated adverse responses 
to NTX. Finally, PRZ+NTX may provide effective treatment for subjects who do not 
respond adequately to either drug alone.
In summary, the current results demonstrate that treatment with PRZ+NTX may provide 
especially effective suppression of alcohol drinking and relapse even in individuals with a 
long history of voluntary heavy alcohol drinking, dependence and relapses. This 
combination treatment is effective in a variety of alcohol drinking patterns (daily, 
intermittent, post-deprivation) and with treatment administered either chronically or “as 
needed”. The combination of these two safe, well-characterized and FDA-approved drugs 
thus offers great promise for effectively treating alcohol use disorders in a broad spectrum of 
patients.
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Figure 1. 
Timeline of sequential studies. These studies were conducted after 1 year of ad libitum 
access to food, water and 20% alcohol, with repetitive temporary alcohol withdrawals, that 
produced alcohol dependence.
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Figure 2. 
Effects of oral prazosin (PRZ, 2 mg/kg) and naltrexone (NTX, 10 mg/kg), alone or in 
combination, on alcohol intake during daily 2-h alcohol access with daily drug treatment 
(Expt. 1, treatment weeks 1-3). Each bar represents data from 12-13 rats. *** p<0.001, ** 
p<0.01, * p<0.05, independent of day. Veh: vehicle.
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Figure 3. 
Effects of oral prazosin (PRZ, 2 mg/kg) and naltrexone (NTX, 10 mg/kg), alone or in 
combination, on alcohol intake during intermittent 2-h alcohol access with daily drug 
treatments (Expt. 2; treatment weeks 4-5). A, B and C indicate tests of PRZ and NTX effects 
on 1 h, 5 min or 2 min intake of a solution of [3% sucrose + 0.125% saccharin] on days with 
no alcohol access (results presented in Fig. 4). Each bar represents data from 12-13 rats. *** 
p<0.001, PRZ+NTX vs vehicle (VEH), independent of day.
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Figure 4. 
Effects of oral prazosin (PRZ, 2 mg/kg) and naltrexone (NTX, 10 mg/kg), alone or in 
combination, on intake of a solution of [3% sucrose + 0.125% saccharin] during 1-h, 5-min 
or 2-min access in Expt. 2 (as noted in Fig. 3). Each bar represents data from 12-13 rats. *** 
p<0.001, ** p<0.01, * p<0.05 vs vehicle (VEH).
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Figure 5. 
Effects of oral prazosin (PRZ, 2 mg/kg) and naltrexone (NTX, 10 mg/kg), alone or in 
combination, on alcohol intake during intermittent 2-h alcohol access with intermittent drug 
treatments (Expt. 3, treatment weeks 6-8). Solid black boxes (██) indicate days on which 
drug treatment was administered. Each bar represents data from 12-13 rats. *** p<0.001, ** 
p<0.01, * p<0.05 vs vehicle (VEH).
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Figure 6. 
Weekly average alcohol and water intakes during all 3 sequential experiments spanning drug 
treatment weeks 1-8. PRE: pretreatment week. Each bar represents data from 12-13 rats. *** 
p<0.001, ** p<0.01, * p<0.05 vs VEH. PRZ: prazosin, NTX: naltrexone, VEH: vehicle.
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Figure 7. 
Effects of the combined oral prazosin (PRZ, 2 mg/kg) + naltrexone (NTX, 10 mg/kg) 
treatment on alcohol intake during post-deprivation reinstatement of alcohol access (Expt. 
4). Rats that had previously received only vehicle (VEH) control treatments in Experiments 
1-3 were restored to unlimited 24-h alcohol access for 4 weeks, followed by 2 weeks of 
alcohol deprivation. The rats received either PRZ+NTX or VEH on the final 2 days of 
alcohol deprivation and on 2 days reinstatement of 2-h/day alcohol access. Each bar 
represents data from 6 rats. ** p<0.01, independent of day.
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Table 1
Body weights before and after 8 consecutive weeks of treatment
Pre-treatment
(g, mean ± SE)
Week 8
(g, mean ± SE)
VEH 616 ± 14 624 ± 14
PRZ 599 ± 15 612 ± 16
NTX 589 ± 18 595 ± 17
PRZ + NTX 587 ± 19 596 ± 21
Each value represents data from 12-13 rats VEH: vehicle; PRZ: prazosin; NTX: naltrexone.
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